The molecular docking results showed that the binding energies of (+)-2-bornanone with DRD3 and SCN2A and eugenol with DRD1 and SLC2A1 were less than-5 kJ·mol−1, indicating that the identified components have good binding with the targets and the main active components of AMS can improve sleep disorders via multiple targets. The gene discussed is SLC2A1; the disease is ablepharon macrostomia syndrome.